Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06357845 · ClinicalTrials.gov registry record · NA
Linking Somatic Mutation Rate With Baseline Exposure in East Palestine
A NA study of Somatic Mutation, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT06357845: Recruiting NA study of Somatic Mutation, sponsored by Case Comprehensive Cancer Center.
NCT06357845 is a NA study of Somatic Mutation that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 500 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06357845, a NA study of Somatic Mutation, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to This research team is conducting this study to develop methods to measure the biological impact of exposure to the chemicals released following the February 3, 2023 train derailment on residents of East Palestine, Ohio, and surrounding communities. The main question it aims to answer is: * What biological impact will be measured based on DNA damage? * In participants who provide a biospecimen, how are biomarker changes related to proximity to the derailment and variations in residents' health histories and behaviors? Participants will: * Complete a brief survey asking about experiences related to the February 3, 2023 train derailment, health experiences, and concerns following the derailment, and background information regarding health history. * Possibly contribute biospecimens such as blood, spit, hair, and/or toenail clippings. * Receive communication about study updates and future research opportunities. * A total of 40 study participants will be recruited to participate in a 90-minute interview. The interviews will be video and audio recorded.
Primary Outcome
The primary outcome measure is somatic mutation rates in association with geographical distance from the train derailment epicenter.
Conditions Studied
Interventions
- OTHER Survey
- OTHER Biological specimen collection
- OTHER Communications about study updates and future research opportunities
- OTHER Qualitative interview
Study Locations (1)
Ohio
- Case Western Reserve University, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-08-16 |
| Est. Completion | 2026-09-30 |
| Phase | NA |
What NCT06357845 shows while recruiting
NCT06357845 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Somatic Mutation appearing as the primary indexed condition, and to 4 interventions - of which Survey is the first listed.
NCT06357845 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06357845 about?
NCT06357845 is a clinical study titled "Linking Somatic Mutation Rate With Baseline Exposure in East Palestine". The goal of this study is to This research team is conducting this study to develop methods to measure the biological impact of exposure to the chemicals released following the February 3, 2023 train derailment on residents of East Palestine, Ohio, and surrounding communities. The main question it a...
What is the current status of trial NCT06357845?
This trial is currently recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2024-08-16. Estimated completion is 2026-09-30.
What conditions does trial NCT06357845 study?
This clinical trial studies the following conditions: Somatic Mutation.
What interventions are being tested in trial NCT06357845?
The interventions under investigation include: Survey (OTHER), Biological specimen collection (OTHER), Communications about study updates and future research opportunities (OTHER), Qualitative interview (OTHER).
Who is sponsoring clinical trial NCT06357845?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06357845 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Somatic Mutation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06357845's enrollment target sits among peer trials
500 193rd of 2000 higher than 1,788 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI